tradingkey.logo
Search
Markets
Watchlist
News
Analysis
Tools
Stock Screener
English
繁体中文
ไทย
Tiếng việt
简体中文
Español
Português
Deutsch
한국어
日本語
tradingkey.logo
Search

Recursion Pharmaceuticals Inc

RXRX
Add to Watchlist
3.000USD
+0.030+1.02%
Close 07-29 16:00（ET）Quotes delayed by 15 min
1.58BMarket Cap
LossP/E TTM

Recursion Pharmaceuticals Inc

3.000
+0.030+1.02%
Overview
Financials
Discussions
Analysis
Company
Financial SummaryIncome StatementBalance SheetCash Flow Statement

Overview

Financials

Discussions

Analysis

Company

Financial SummaryIncome StatementBalance SheetCash Flow Statement

RXRX Financials

See Recursion Pharmaceuticals Inc's financials through an all-in-one data dashboard designed for smart investors. This provides you with financial analysis by organizing complex financial statements into customizable views. Access the latest annual financial report or break down performance quarter-by-quarter using the income statement, balance sheet, and cash flow statement. With real-time financial indicators at your fingertips, monitoring a company's market health over time has never been easier.

Recursion Pharmaceuticals Inc Earnings Date

Latest Release
May 6, 2026
EPS / Forecast
-0.22/-0.27
Revenue / Forecast
6.47M/15.78M
See Upcoming Earnings >>
Period
FY2025 Earnings
Revenue(YoY)
74.68M
26.92%
EPS(YoY)
-1.44
14.78%
Analyst Rating
HOLD
2026/07/29
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
Financial Indicators
EPS
55.84%-0.22
61.03%-0.21
-7.03%-0.36
-2.27%-0.41
-29.86%-0.50
-31.70%-0.53
22.46%-0.34
-3.17%-0.40
-13.56%-0.39
-30.45%-0.40
---0.44
---0.39
---0.34
---0.31
---1.06
----
----
----
----
----
Revenue
-56.11%6.47M
681.74%35.54M
-80.16%5.17M
33.34%19.22M
6.89%14.74M
-58.26%4.55M
147.62%26.08M
30.86%14.42M
13.68%13.79M
-20.36%10.89M
-19.96%10.53M
43.56%11.02M
127.53%12.13M
439.91%13.68M
419.34%13.16M
201.06%7.67M
108.16%5.33M
--2.53M
--2.53M
1270.43%2.55M
Net Profit
41.97%-117.50M
39.56%-108.12M
-69.29%-162.25M
-76.23%-171.90M
-121.60%-202.49M
-92.38%-178.91M
-3.04%-95.84M
-27.13%-97.54M
-39.87%-91.37M
-61.75%-93.00M
-53.89%-93.02M
-17.03%-76.73M
-16.70%-65.33M
11.46%-57.49M
-27.45%-60.45M
-51.06%-65.56M
-82.24%-55.98M
---64.93M
---47.43M
-129.11%-43.40M
Net Margin
-32.21%-1815.57%
92.27%-304.24%
-753.23%-3135.32%
-32.17%-894.23%
-107.31%-1373.26%
-360.89%-3935.46%
58.39%-367.46%
2.85%-676.56%
-23.04%-662.41%
-103.12%-853.88%
---883.10%
---696.43%
---538.38%
---420.39%
---695.47%
----
----
----
----
----
Gross Margin
-93.54%-92.99%
132.98%59.83%
-442.36%-183.81%
-113.48%-4.88%
-352.17%-48.04%
-2056.44%-181.43%
1743.89%53.69%
143.88%36.19%
836.22%19.05%
-55.28%9.27%
---3.27%
--14.84%
---2.59%
--20.74%
---43.06%
----
----
----
----
----
Debt to assets ratio
-35.98%1.23%
-33.21%1.27%
-62.38%1.49%
-55.94%1.76%
850.16%1.92%
984.56%1.89%
1269.88%3.95%
1356.24%4.00%
-31.18%0.20%
93.55%0.17%
--0.29%
--0.27%
--0.29%
--0.09%
--0.11%
----
----
----
----
----
Income Statement
Revenue
-56.11%6.47M
681.74%35.54M
-80.16%5.17M
33.34%19.22M
6.89%14.74M
-58.26%4.55M
147.62%26.08M
30.86%14.42M
13.68%13.79M
-20.36%10.89M
-19.96%10.53M
43.56%11.02M
127.53%12.13M
439.91%13.68M
419.34%13.16M
201.06%7.67M
108.16%5.33M
--2.53M
--2.53M
1270.43%2.55M
Operating profit
32.85%-128.50M
41.05%-108.33M
-75.08%-172.20M
-75.28%-176.23M
-98.64%-191.37M
-85.76%-183.77M
1.20%-98.35M
-23.04%-100.54M
-40.30%-96.34M
-62.23%-98.93M
-59.09%-99.55M
-28.91%-81.72M
-22.66%-68.67M
6.12%-60.98M
-34.85%-62.57M
-54.88%-63.39M
-83.64%-55.98M
---64.96M
---46.40M
-124.67%-40.93M
Net Profit
41.97%-117.50M
39.56%-108.12M
-69.29%-162.25M
-76.23%-171.90M
-121.60%-202.49M
-92.38%-178.91M
-3.04%-95.84M
-27.13%-97.54M
-39.87%-91.37M
-61.75%-93.00M
-53.89%-93.02M
-17.03%-76.73M
-16.70%-65.33M
11.46%-57.49M
-27.45%-60.45M
-51.06%-65.56M
-82.24%-55.98M
---64.93M
---47.43M
-129.11%-43.40M
Balance Sheet
Current assets
21.47%709.56M
13.80%812.85M
50.60%714.11M
12.40%587.16M
70.00%584.14M
63.02%714.27M
15.50%474.17M
21.20%522.38M
-30.18%343.62M
-23.11%438.14M
-14.76%410.52M
-21.06%431.02M
-20.56%492.13M
6.56%569.81M
-19.85%481.62M
-15.69%546.00M
179.26%619.46M
--534.72M
--600.87M
--647.63M
Total current liabilities
-8.65%129.70M
-21.21%147.71M
42.44%155.10M
90.54%164.03M
92.07%141.98M
101.21%187.47M
15.69%108.89M
-24.46%86.08M
-19.78%73.92M
-7.08%93.17M
13.35%94.12M
17.91%113.96M
7.52%92.15M
114.89%100.27M
93.36%83.04M
227.19%96.65M
219.15%85.70M
--46.66M
--42.94M
--29.54M
Total assets
2.63%1.34B
1.76%1.47B
92.64%1.40B
67.86%1.30B
133.98%1.31B
121.60%1.45B
15.17%726.50M
16.37%775.86M
-11.08%557.85M
-6.79%653.70M
3.15%630.83M
-0.86%666.70M
-14.56%627.37M
14.90%701.29M
-7.15%611.53M
-3.73%672.51M
170.03%734.32M
--610.35M
--658.61M
--698.59M
Total liabilities
-15.23%314.75M
-17.05%343.26M
74.60%352.58M
100.20%383.21M
136.95%371.29M
117.50%413.82M
4.71%201.94M
-3.20%191.41M
-20.54%156.70M
-11.70%190.26M
-13.71%192.86M
-15.83%197.74M
-18.09%197.19M
219.67%215.48M
275.16%223.50M
320.46%234.94M
324.89%240.75M
--67.41M
--59.57M
--55.88M
Total equity
9.72%1.02B
9.29%1.13B
99.59%1.05B
57.27%919.15M
132.82%933.95M
123.28%1.03B
19.77%524.56M
24.63%584.45M
-6.75%401.15M
-4.60%463.44M
12.87%437.97M
7.17%468.96M
-12.84%430.18M
-10.52%485.81M
-35.22%388.03M
-31.92%437.58M
129.27%493.57M
--542.94M
--599.03M
--642.71M
Cash Flow Statement
Net operating income
38.54%-81.10M
60.09%-46.07M
-98.16%-117.36M
7.06%-76.42M
-28.99%-131.96M
-55.82%-115.43M
18.78%-59.23M
-21.87%-82.22M
-39.53%-102.30M
-65.54%-74.08M
-33.70%-72.92M
-9.48%-67.47M
-194.74%-73.32M
26.83%-44.75M
-65.04%-54.54M
-83.11%-61.62M
351.63%77.39M
---61.16M
---33.05M
---33.65M
Net investment
95.35%-338.00K
-100.45%-1.24M
44.13%-2.55M
-38.88%-5.81M
-9.27%-7.27M
11171.38%275.46M
-1214.70%-4.56M
-103.70%-4.18M
-24.59%-6.65M
68.82%-2.49M
-100.65%-347.00K
-141.56%-2.05M
-103.73%-5.34M
84.73%-7.98M
127.33%52.98M
179.52%4.94M
838.07%143.30M
---52.24M
---193.87M
---6.21M
Net financing
-108.56%-3.47M
1140.77%132.01M
1426.79%251.34M
-62.88%97.66M
191.62%40.53M
-86.81%10.64M
-69.38%16.46M
6848.03%263.12M
623.05%13.90M
-45.23%80.66M
2200.60%53.77M
41.94%3.79M
-7.77%1.92M
3779.24%147.26M
121.06%2.34M
-99.42%2.67M
-2.34%2.08M
--3.80M
---11.10M
--463.70M

FAQs

What is the total revenue of Recursion Pharmaceuticals Inc?

According to Recursion Pharmaceuticals Inc's FY2025 earnings report, its total revenue reached 74.68M, with a year-on-year change of 58.84M.

What are the current assets of Recursion Pharmaceuticals Inc?

According to Recursion Pharmaceuticals Inc's FY2025 earnings report, its current assets were 812.85M, with a year-on-year change of 13.80.

What are the total assets of Recursion Pharmaceuticals Inc?

According to Recursion Pharmaceuticals Inc's FY2025 earnings report, its total assets of Recursion Pharmaceuticals Inc were 1.47B, with a year-on-year change of 1.76.

What are the total liabilities of Recursion Pharmaceuticals Inc?

According to Recursion Pharmaceuticals Inc's FY2025 earnings report, its total liabilities of Recursion Pharmaceuticals Inc were 343.26M, with a year-on-year change of -17.05.

What is the total equity of Recursion Pharmaceuticals Inc?

According to Recursion Pharmaceuticals Inc's FY2025 earnings report, its total equity of Recursion Pharmaceuticals Inc was 1.13B, with a year-on-year change of 9.29.

What is the net operating income of Recursion Pharmaceuticals Inc?

According to Recursion Pharmaceuticals Inc's FY2025 earnings report, its net operating income of Recursion Pharmaceuticals Inc was -648.13M, with a year-on-year change of -35.31.

What is the net investment of Recursion Pharmaceuticals Inc?

According to Recursion Pharmaceuticals Inc's FY2025 earnings report, its net investment of Recursion Pharmaceuticals Inc was -16.87M, with a year-on-year change of -106.49.

What is the net financing of Recursion Pharmaceuticals Inc?

According to Recursion Pharmaceuticals Inc's FY2025 earnings report, its net financing of Recursion Pharmaceuticals Inc was 521.53M, with a year-on-year change of 71.49.

What is the Earnings Per Share (EPS) of Recursion Pharmaceuticals Inc?

According to Recursion Pharmaceuticals Inc's FY2025 earnings report, its Earnings Per Share (EPS) was -1.44, with a year-on-year change of 14.78.

What is the net income of Recursion Pharmaceuticals Inc?

According to Recursion Pharmaceuticals Inc's FY2025 earnings report, its net income was -644.76M, with a year-on-year change of -39.06.

What is the net margin of Recursion Pharmaceuticals Inc?

According to Recursion Pharmaceuticals Inc's FY2025 earnings report, its net profit margin was -863.35, with a year-on-year change of -9.56.

What is the gross margin of Recursion Pharmaceuticals Inc?

According to Recursion Pharmaceuticals Inc's FY2025 earnings report, its gross margin was 4.99, with a year-on-year change of -78.40.

What is the debt-to-asset ratio of Recursion Pharmaceuticals Inc?

According to Recursion Pharmaceuticals Inc's FY2025 earnings report, its debt-to-asset ratio was 1.27, with a year-on-year change of -33.21.

What is the Return on Equity (ROE) of Recursion Pharmaceuticals Inc?

According to Recursion Pharmaceuticals Inc's FY2025 earnings report, its Return on Equity (ROE) was -59.54, with a year-on-year change of 3.80.

What is the Return on Assets (ROA) of Recursion Pharmaceuticals Inc?

According to Recursion Pharmaceuticals Inc's FY2025 earnings report, its Return on Assets (ROA) was -44.12, with a year-on-year change of -0.02.

What is the operating profit of Recursion Pharmaceuticals Inc?

According to Recursion Pharmaceuticals Inc's FY2025 earnings report, its operating profit was -648.13M, with a year-on-year change of -35.31.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.
General Terms of Use
Privacy Policy
Cookie Policy